Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 988 across all filing types
Latest filing 2025-05-21 Director's Dealing
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
App 3Z Final Director Interests - K McCann 2 pages 196.7KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Z Final Director’s Interest Notice' and references ASX listing rule 3.19A.3 and section 205G of the Corporations Act. It details the director's relevant interests in securities and notes the date the director ceased to be a director. The content focuses on personal shareholdings and interests of a director, including securities held directly or indirectly. There is no financial performance data, audit information, or report content. This matches the definition of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades). The document length is short and specific to director interests, confirming the classification as DIRS with high confidence.
2025-05-21 English
CURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTS
Regulatory Filings
2025-05-21 English
Telix Annual General Meeting Chairman and CEO Addresses 12 pages 265.6KB
AGM Information Classification · 95% confidence The document is an ASX announcement containing the Chairman and CEO addresses delivered at the Annual General Meeting (AGM) of Telix Pharmaceuticals Limited. It includes reflections on company history, financial performance, strategy, governance, board renewal, and future outlook. The content is typical of speeches or presentations given at an AGM rather than a full annual report or financial statements. The document is lengthy (15,000 characters) and contains detailed narrative but does not include comprehensive financial statements or audit information. It is clearly labeled as AGM Chairman and CEO addresses and references the AGM event date and location. Therefore, the document fits the category of AGM Information (AGM-R).
2025-05-20 English
Telix Annual General Meeting Presentation 15 pages 1.6MB
AGM Information Classification · 95% confidence The document is a detailed presentation related to the Annual General Meeting (AGM) of Telix Pharmaceuticals, including strategic updates, product pipeline, market expansion, and financial highlights. It explicitly mentions the AGM date and time, and the content is structured as a presentation with slides and images omitted. It includes forward-looking statements, business strategy, product approvals, and clinical trial updates, typical of investor presentations at AGMs. There is no indication that this is the full annual report, audit report, or earnings release. The document is not a voting result announcement or a regulatory filing. The presence of detailed business strategy and financial highlights in a presentation format for the AGM strongly indicates this is AGM Information (AGM-R).
2025-05-20 English
Telix Results of Annual General Meeting 5 pages 246.1KB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an ASX announcement titled 'Telix Results of Annual General Meeting' dated 21 May 2025. It contains detailed voting results for each resolution proposed at the AGM, including votes for, against, abstentions, and the final outcome of each resolution. The document references compliance with section 251AA of the Corporations Act 2001, which pertains to the disclosure of voting results at general meetings. The content is focused on the results of the shareholder votes at the AGM rather than the AGM materials or presentations themselves. The document length is over 12,000 characters, indicating it is a full report of voting results rather than a brief announcement. Therefore, this document fits the category of 'Declaration of Voting Results & Voting Rights Announcements' (DVA).
2025-05-20 English
Pending Release of Shares from Voluntary Escrow 2 pages 146.0KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement from Telix Pharmaceuticals Limited regarding the pending release of shares from voluntary escrow. It references compliance with ASX Listing Rule 3.10A and details the number of shares and release date. The content is focused on a specific capital event related to share escrow release, which is a capital structure update. There are no financial statements, earnings data, or management discussion present. The document is not a full report but an announcement of a capital-related event. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (6219 characters) supports it being a detailed announcement rather than a brief notice or a full report.
2025-05-18 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.